Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

60.65 +3.57 (+6.25%)
Streaming Delayed Price Updated: 1:46 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
36 37 Next >
News headline image
3 Surprisingly Underrated Stocks to Buy Right Now ↗
These stocks deserve more respect than they're getting. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks ↗
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
News headline image
3 Clever Tricks to Find Winning Biotech Stocks ↗
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
News headline image
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M ↗
 
Via Benzinga
Topics Earnings
News headline image
What 13 Analyst Ratings Have To Say About CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
Why CRISPR Therapeutics Stock Is Jumping Today ↗
Analysts continue to like this gene-editing stock. 
Via The Motley Fool
News headline image
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗
Helping save and improve patients' lives in novel ways can be a lucrative activity. 
Via The Motley Fool
News headline image
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead ↗
 
Via Benzinga
News headline image
Stocks to Watch This Week’s Top 7 Wall Street Upgrades ↗
With the market printing some red ink recently, investors may take greater confidence in the top Wall Street upgrades this week. 
Via InvestorPlace
News headline image
Gene Therapy Breakthroughs On The Horizon ↗
Vertex Pharmaceuticals and CRISPR Therapeutics, alongside bluebird bio, are penning a new chapter in the story of gene therapy for sickle cell disease. 
Via Talk Markets
News headline image
3 Green Flags for Biotech Stocks in 2023 and Beyond ↗
The industry is changing rapidly, and for the better. 
Via The Motley Fool
News headline image
1 No-Brainer Cathie Wood Stock to Buy Hand Over Fist in August ↗
Crispr Therapeutics could be incredibly undervalued right now. 
Via The Motley Fool
News headline image
The Latest Analyst Ratings for CRISPR Therapeutics ↗
 
Via Benzinga
News headline image
The 3 Most Undervalued Cathie Wood Stocks to Buy Now: August 2023 ↗
Even if Cathie Wood stocks in ARK fell from grace, these three portfolio picks remain undervalued and ideal investments. 
Via InvestorPlace
News headline image
Missed Out on CRISPR Therapeutics? My Best Biotech Stock to Buy and Hold ↗
CRISPR Therapeutics is an intriguing biotech stock to consider now. 
Via The Motley Fool
News headline image
3 Reasons to Buy CRISPR Therapeutics Stock, and 1 Reason to Sell ↗
This company is in a critical period, and it could soon grow significantly. 
Via The Motley Fool
News headline image
Ready to Buy the Dip? CRISPR Therapeutics Stock Is a Smart Buy ↗
Its shares tumbled due to factors outside its control, but the biotech still has substantial long-term potential. 
Via The Motley Fool
News headline image
Cathie Wood Buys Roblox, Palantir Dips — Ark Invest Seizes Buying Opportunities Following Earnings Reports ↗
 
Via Benzinga
News headline image
The 3 Best Biotech Stocks to Buy in August ↗
Even as healthcare stocks suffer from post-pandemic fatigue, these three of the best biotech stocks to buy and ride the wave of good news. 
Via InvestorPlace
News headline image
2 Supercharged Growth Stocks That Could Make You Richer ↗
These two biotechs are poised for a sustained period of growth. 
Via The Motley Fool
News headline image
2 Great Stocks Under $100 to Buy and Hold for 10 Years ↗
Neither has performed well over the past year, but investors would do well to focus on the longer term. 
Via The Motley Fool
News headline image
Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 400 points on Tuesday. Here are some big stocks recording gains in today’s session. Paymentus Holdings, Inc. (NYSE: PAY) shares rose 29.4% to... 
Via Benzinga
News headline image
Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Nuburu, Inc. (NYSE: BURU) shares jumped 185.6% to $1.6593 after the company announced contract with NASA to demonstrate feasibility of power beaming in space using the company’s blue laser... 
Via Benzinga
News headline image
3 Biotech Stocks That Analysts Are Drooling Over ↗
With the medical science realm representing one of the most complex markets, these top analyst biotech picks can be worth your time. 
Via InvestorPlace
News headline image
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now ↗
Biotech stocks can be a lucrative investment opportunity, these three biotech stocks to buy now are among analyst favorites. 
Via InvestorPlace
News headline image
Vertex Pharma Raises Annual Forecast On Strong Uptake For Cystic Fibrosis Drug, Analysts Says Investors' Focus On Non-CF Pipeline ↗
Vertex Pharmaceuticals Inc's (NASDAQ: VRTX) Q2 sales increased 14% to $2.49 billion, beating the consensus of $2.41 bill 
Via Benzinga
News headline image
3 Hidden Penny Stocks That Could Turn $100 into $10,000 ↗
These penny stocks have multibagger upside potential with great margins of safety, according to Wall Street analysts. 
Via InvestorPlace
News headline image
These 2 Stocks Are Heading for a Big Moment. Time to Buy? ↗
Both stocks have climbed in the double digits this year. 
Via The Motley Fool
News headline image
This 1 Innovation Could Make These 2 Biotechs Soar by 2030 ↗
Simplifying the cell therapy manufacturing process could be worth a lot of money. 
Via The Motley Fool
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.